Codexis (CDXS) vs. Regulus Therapeutics (RGLS) Head to Head Analysis
Codexis (NASDAQ: CDXS) and Regulus Therapeutics (NASDAQ:RGLS) are both small-cap industrial products companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.
Institutional & Insider Ownership
63.6% of Codexis shares are owned by institutional investors. Comparatively, 21.9% of Regulus Therapeutics shares are owned by institutional investors. 9.8% of Codexis shares are owned by insiders. Comparatively, 4.8% of Regulus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Codexis and Regulus Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Codexis||$43.16 million||7.73||-$15.16 million||($0.41)||-16.83|
|Regulus Therapeutics||$257,999.00||547.09||-$73.96 million||($1.54)||-0.88|
Codexis has higher revenue and earnings than Regulus Therapeutics. Codexis is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares Codexis and Regulus Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
Codexis has a beta of -1.43, meaning that its stock price is 243% less volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500.
This is a summary of recent ratings and recommmendations for Codexis and Regulus Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Codexis currently has a consensus target price of $7.19, suggesting a potential upside of 4.17%. Regulus Therapeutics has a consensus target price of $4.10, suggesting a potential upside of 201.47%. Given Regulus Therapeutics’ higher possible upside, analysts plainly believe Regulus Therapeutics is more favorable than Codexis.
Codexis beats Regulus Therapeutics on 10 of the 13 factors compared between the two stocks.
Codexis Company Profile
Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company’s pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company’s Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.
Receive News & Stock Ratings for Codexis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis Inc. and related stocks with our FREE daily email newsletter.